Syneron Medical Ltd (ELOS) Tops Q2 EPS by 1c

Syneron Medical Ltd (NASDAQ: ELOS) reported Q2 EPS of $0.07, $0.01 better than the analyst estimate of $0.06. Revenue for the quarter came in at $73.5 million versus the consensus estimate of $70.93 million.

North America Body Shaping Division Highlights:

• Sold 63 UltraShape™ systems.
• Generated strong double-digit sequential growth of per procedure Focal Treatment Zones (FTZ).
• Strong acceptance of Syneron's unique combination treatment with VelaShape and UltraShape contributes to VelaShape III sales and generates superior body shaping clinical outcome.
• Advanced clinical trial activity in support of expanding UltraShape's FDA cleared indications for use.

Amit Meridor, Chief Executive Officer of Syneron, said, "We achieved another solid quarter in our North America Body Shaping Division, driven by the expansion of our sales team and marketing initiatives. We remain on track with our UltraShape revenue plan for the year. We are also investing in clinical trials to expand our FDA UltraShape clinical indications for additional body areas."

North America Aesthetic Division Highlights:

• Generated strong PicoWay™ sales.
• PicoWay received FDA clearance in the U.S. for treatment of pigmented lesions.
• Launched Profound™ RF micro-needle technology for minimally invasive sub-mental and face lift treatments, generating positive initial traction.

Mr. Meridor added, "Growth in the North America Aesthetic Division was driven by the ongoing launch of PicoWay, good results from the Gentle Pro family of dual wavelength laser systems, and launch of the Profound minimally invasive micro-needle RF system. FDA clearance of PicoWay for treatment of pigmented lesions further expands its market opportunity and strengthens our confidence in its growth potential. PicoWay also has strong potential growth trajectory outside of North America. We were pleased to receive regulatory clearance in the important Korean market in late July."

For earnings history and earnings-related data on Syneron Medical Ltd (ELOS) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c